In this issue:
KEYNOTE-042: PD-L1 TPS and survival
Corticosteroids and immunotherapy
Erlotinib and stage IIIA-N2 NSCLC
Nintedanib and malignant mesothelioma
Screening for ALK gene rearrangement
Patient traits and tumour genomics
Home-based rehabilitation
KEYNOTE-001: 5-year survival data
Whole-body MRI: worth it?
EBUS and radiotherapy planning
Please login below to download this issue (PDF)